{"id":"personalized-dapt-duration","safety":{"commonSideEffects":[{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Major bleeding"},{"rate":null,"effect":"Minor bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a treatment strategy rather than a single drug entity. It involves customizing the duration of dual antiplatelet therapy based on patient-specific bleeding and ischemic risk profiles, typically assessed through clinical scoring systems or biomarkers. The approach aims to optimize the balance between reducing stent thrombosis risk and minimizing bleeding complications by individualizing therapy duration beyond standard 12-month protocols.","oneSentence":"Personalized DAPT duration tailors the length of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) to individual patient risk factors rather than using a fixed treatment duration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:15.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) post-percutaneous coronary intervention (PCI) with stent placement"},{"name":"Stable coronary artery disease post-PCI with stent placement"}]},"trialDetails":[{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT04135989","phase":"PHASE4","title":"Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2020-01-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome","enrollment":2106},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Personalized DAPT duration","genericName":"Personalized DAPT duration","companyName":"Federico II University","companyId":"federico-ii-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Personalized DAPT duration tailors the length of dual antiplatelet therapy (aspirin plus P2Y12 inhibitor) to individual patient risk factors rather than using a fixed treatment duration. Used for Acute coronary syndrome with percutaneous coronary intervention and stent placement, Stable coronary artery disease with percutaneous coronary intervention and stent placement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}